Does the media favor MYGN or CRVS?

In the previous week, Myriad Genetics had 6 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 8 mentions for Myriad Genetics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Myriad Genetics' score of 0.64 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor GLUE or MYGN?

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 8 articles in the media. Monte Rosa Therapeutics' average media sentiment score of 0.84 beat Myriad Genetics' score of 0.64 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MYGN or KURA?

In the previous week, Myriad Genetics and Myriad Genetics both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.64 beat Kura Oncology's score of 0.43 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SANA or MYGN?

In the previous week, Sana Biotechnology and Sana Biotechnology both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.64 beat Sana Biotechnology's score of 0.59 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MYGN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -13.96% -16.09% -8.10% Savara N/A -90.28% -68.95%

Does the media prefer MYGN or SVRA?

In the previous week, Myriad Genetics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Myriad Genetics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Myriad Genetics' score of 0.64 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Myriad Genetics (MYGN) Competitors

$3.42 +0.06 (+1.79%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.42 0.00 (-0.15%)

As of 09/11/2026 07:50 PM Eastern

Compare

MYGN vs. CRVS, GLUE, KURA, SANA, and SVRA

Should you buy Myriad Genetics stock or one of its competitors? Myriad Genetics's main competitors and comparable companies include Corvus Pharmaceuticals (CRVS), Monte Rosa Therapeutics (GLUE), Kura Oncology (KURA), Sana Biotechnology (SANA), and Savara (SVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Corvus Pharmaceuticals?

Myriad Genetics (NASDAQ:MYGN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Myriad Genetics presently has a consensus target price of $3.12, suggesting a potential downside of 8.77%. Corvus Pharmaceuticals has a consensus target price of $33.33, suggesting a potential upside of 158.20%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Myriad Genetics had 6 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 8 mentions for Myriad Genetics and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Myriad Genetics' score of 0.64 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Corvus Pharmaceuticals has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corvus Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Myriad Genetics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Monte Rosa Therapeutics currently has a consensus target price of $28.50, indicating a potential upside of 102.56%. Myriad Genetics has a consensus target price of $3.12, indicating a potential downside of 8.77%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

In the previous week, Monte Rosa Therapeutics and Monte Rosa Therapeutics both had 8 articles in the media. Monte Rosa Therapeutics' average media sentiment score of 0.84 beat Myriad Genetics' score of 0.64 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Myriad Genetics has a net margin of -13.96% compared to Monte Rosa Therapeutics' net margin of -560.85%. Myriad Genetics' return on equity of -16.09% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Myriad Genetics	-13.96%	-16.09%	-8.10%

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Monte Rosa Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	9.71	-$38.63M	-$1.76	N/A
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A

Monte Rosa Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Summary

Monte Rosa Therapeutics and Myriad Genetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Kura Oncology?

Myriad Genetics (NASDAQ:MYGN) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Kura Oncology has lower revenue, but higher earnings than Myriad Genetics. Kura Oncology is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A
Kura Oncology	$67.48M	15.02	-$278.67M	-$3.37	N/A

Myriad Genetics has a net margin of -13.96% compared to Kura Oncology's net margin of -384.30%. Myriad Genetics' return on equity of -16.09% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Kura Oncology	-384.30%	-207.18%	-45.17%

99.0% of Myriad Genetics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Myriad Genetics currently has a consensus target price of $3.12, suggesting a potential downside of 8.77%. Kura Oncology has a consensus target price of $25.40, suggesting a potential upside of 123.00%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Kura Oncology is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Myriad Genetics and Myriad Genetics both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.64 beat Kura Oncology's score of 0.43 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Myriad Genetics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

Myriad Genetics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Sana Biotechnology has higher earnings, but lower revenue than Myriad Genetics. Sana Biotechnology is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A

Sana Biotechnology has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Myriad Genetics	-13.96%	-16.09%	-8.10%

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 1.9% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sana Biotechnology presently has a consensus target price of $9.33, suggesting a potential upside of 198.19%. Myriad Genetics has a consensus target price of $3.12, suggesting a potential downside of 8.77%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, research analysts plainly believe Sana Biotechnology is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

In the previous week, Sana Biotechnology and Sana Biotechnology both had 8 articles in the media. Myriad Genetics' average media sentiment score of 0.64 beat Sana Biotechnology's score of 0.59 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

Summary

Sana Biotechnology beats Myriad Genetics on 9 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Savara?

Myriad Genetics (NASDAQ:MYGN) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Savara has lower revenue, but higher earnings than Myriad Genetics. Savara is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Myriad Genetics presently has a consensus price target of $3.12, indicating a potential downside of 8.77%. Savara has a consensus price target of $10.00, indicating a potential upside of 88.68%. Given Savara's stronger consensus rating and higher possible upside, analysts clearly believe Savara is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Savara	N/A	-90.28%	-68.95%

Myriad Genetics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Savara has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

In the previous week, Myriad Genetics had 6 more articles in the media than Savara. MarketBeat recorded 8 mentions for Myriad Genetics and 2 mentions for Savara. Savara's average media sentiment score of 1.84 beat Myriad Genetics' score of 0.64 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Savara beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$327.12M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.87	14.18	274.94	25.33
Price / Sales	0.40	1,375.01	685.45	111.12
Price / Cash	0.91	106.50	76.65	51.52
Price / Book	0.87	15.12	10.33	6.20
Net Income	-$365.90M	-$22.86M	$3.50B	$358.50M
7 Day Performance	7.21%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.88%	-0.02%	-0.41%	-2.77%
1 Year Performance	-52.76%	40.64%	19.21%	7.63%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	1.0802 of 5 stars	$3.42 +1.8%	$3.12 -8.8%	-55.5%	$327.12M	$824.50M	N/A	2,700	Analyst Forecast Gap Down
CRVS Corvus Pharmaceuticals	2.3057 of 5 stars	$14.39 flat	$33.33 +131.6%	+113.0%	$1.21B	N/A	N/A	30	Positive News Gap Down
GLUE Monte Rosa Therapeutics	2.4743 of 5 stars	$13.84 flat	$28.50 +105.9%	+187.7%	$1.18B	$123.67M	N/A	90	Analyst Forecast
KURA Kura Oncology	3.4982 of 5 stars	$13.25 flat	$25.40 +91.7%	+29.1%	$1.18B	$67.48M	N/A	130
SANA Sana Biotechnology	2.8692 of 5 stars	$3.85 flat	$9.33 +142.4%	-7.9%	$1.15B	N/A	N/A	380	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. CRVS, GLUE, KURA, SANA, and SVRA

How does Myriad Genetics compare to Corvus Pharmaceuticals?

Summary

How does Myriad Genetics compare to Monte Rosa Therapeutics?

Summary

How does Myriad Genetics compare to Kura Oncology?

Summary

How does Myriad Genetics compare to Sana Biotechnology?

Summary

How does Myriad Genetics compare to Savara?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. CRVS, GLUE, KURA, SANA, and SVRA

How does Myriad Genetics compare to Corvus Pharmaceuticals?

Do analysts rate MYGN or CRVS?

Does the media favor MYGN or CRVS?

Is MYGN or CRVS more profitable?

Do institutionals and insiders believe in MYGN or CRVS?

Which has better earnings & valuation, MYGN or CRVS?

Which has more risk & volatility, MYGN or CRVS?

Summary

How does Myriad Genetics compare to Monte Rosa Therapeutics?

Do analysts rate GLUE or MYGN?

Does the media favor GLUE or MYGN?

Is GLUE or MYGN more profitable?

Do insiders and institutionals have more ownership in GLUE or MYGN?

Which has higher valuation and earnings, GLUE or MYGN?

Which has more risk & volatility, GLUE or MYGN?

Summary

How does Myriad Genetics compare to Kura Oncology?

Which has higher earnings & valuation, MYGN or KURA?

Is MYGN or KURA more profitable?

Do institutionals and insiders hold more shares of MYGN or KURA?

Do analysts prefer MYGN or KURA?

Does the media favor MYGN or KURA?

Which has more risk & volatility, MYGN or KURA?

Summary

How does Myriad Genetics compare to Sana Biotechnology?

Which has better earnings & valuation, SANA or MYGN?

Is SANA or MYGN more profitable?

Do institutionals and insiders hold more shares of SANA or MYGN?

Do analysts prefer SANA or MYGN?

Does the media refer more to SANA or MYGN?

Which has more volatility & risk, SANA or MYGN?

Summary

How does Myriad Genetics compare to Savara?

Do institutionals and insiders believe in MYGN or SVRA?

Which has preferable valuation & earnings, MYGN or SVRA?

Do analysts prefer MYGN or SVRA?

Is MYGN or SVRA more profitable?

Which has more risk & volatility, MYGN or SVRA?

Does the media prefer MYGN or SVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools